OK-432 therapy for lymphangiomas

Arch Otolaryngol Head Neck Surg. 1996 Nov;122(11):1195-9. doi: 10.1001/archotol.1996.01890230041009.


Objective: To assess the efficacy of OK-432 sclerotherapy in the treatment of lymphangiomas.

Design: Nonrandomized trial; follow-up, 4 to 29 months.

Setting: Academic tertiary referral medical center.

Patients: Six children with presumed lymphangiomas; age range at initial treatment, 1 month to 7 years 10 months.

Intervention: Fluoroscopically guided cyst aspiration, cystography, and injection of OK-432.

Outcome measures: Clinical and radiographic comparisons before and after therapy.

Results: Complete response in 2 macrocystic lymphangiomas; no response in 3 microcystic lymphangiomas; and no response in 1 venous malformation.

Conclusion: OK-432 sclerotherapy may be effective treatment for macrocystic lymphangiomas.

Publication types

  • Clinical Trial

MeSH terms

  • Child
  • Child, Preschool
  • Female
  • Follow-Up Studies
  • Head and Neck Neoplasms / diagnostic imaging
  • Head and Neck Neoplasms / therapy*
  • Humans
  • Infant
  • Lymphangioma, Cystic / diagnostic imaging
  • Lymphangioma, Cystic / therapy*
  • Male
  • Picibanil / therapeutic use*
  • Radiography
  • Sclerosing Solutions / therapeutic use*
  • Sclerotherapy / methods


  • Sclerosing Solutions
  • Picibanil